Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 7090 results found since Jan 2013.

Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience
CONCLUSIONS: A difference in CR and PFS favored a more aggressive protocol, but the toxicity of the multiagent combinations was significantly higher. The prognosis in younger was better than in older patients, with higher rates of CR, PFS, and OS, although not statistically significant. Overall treatment outcomes are encouraging; however, there is a real need for an adaptive approach for older patients and balancing among the effectiveness and side effects.PMID:36309861
Source: The Israel Medical Association Journal - October 30, 2022 Category: General Medicine Authors: Miri Zektser Anat Rabinovich Uri Grinbaum Tzvi Porges Aya Gozlan Anna Gourevitch Kayed Al-Athamen Orit Barrett Ido Peles Tehila Kaisman-Elbaz Etai Levi Source Type: research

Renal transplantation across the donor-specific antibody barrier: Graft outcome and cancer risk after desensitization therapy
Conclusion When compared to renal transplantation without DSA, desensitization therapy for DSA resulted in equivalent renal transplant outcome but potentially increased risk of urothelial carcinoma after transplantation.
Source: Journal of the Formosan Medical Association - December 24, 2015 Category: Journals (General) Source Type: research

Boston Medical Center to pay $1.1M to settle fraud, whistleblower allegations
Boston Medical Center has agreed to pay $1.1 million to settle allegations that it improperly billed Medicare and Medicaid. The Department of Justice said today in prepared remarks that the hospital had billed Medicare for more units of an expensive cancer drug, called Rituxan, than it had infused in its patients. The federal government also said Boston Medical Center improperly billed Medicare and Medicaid for services at its pre-surgical treatment center, though those treatments had been covered…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 14, 2016 Category: Pharmaceuticals Authors: Jessica Bartlett Source Type: news

The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours
Conclusion High levels of anti-HBs may have a protective effect against the reactivation of HBV especially in patients with haematological malignancies who received immunosuppressive anticancer therapy.
Source: Journal of International Medical Research - May 24, 2016 Category: Research Authors: Yilmaz, B., Erdem, D., Teker, F., Goren, I., Yildirim, B., Kut, E., Sarikaya, D., Atay, M. H., Yucel, I. Tags: Clinical Reports Source Type: research

Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis
Conclusions RTX treatment in IMN was efficient, well tolerated and safe. More than 60% patients can reach partial remission or CR in 24 months, and relapse is rare. Adverse events of RTX are mostly infusion-related reactions and generally mild.
Source: Chinese Medical Sciences Journal - April 6, 2018 Category: General Medicine Source Type: research